Scilex Holding (SCLX) Amortization of Deferred Charges (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Amortization of Deferred Charges of $1.0 million for Q1 2026, up 151.34% on a QoQ basis from $409000.0 in Q4 2025.
Scilex Holding (SCLX) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Amortization of Deferred Charges for 6 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges changed N/A year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.4 million (up 404.21% YoY), while the FY2025 annual figure was $409000.0, up 29.43% from the prior year.
- Amortization of Deferred Charges came in at $1.0 million for Q1 2026 at Scilex Holding, up from $409000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $1.9 million in Q1 2022, with the low at $1000.0 in Q2 2023.
- Average Amortization of Deferred Charges over 5 years is $381538.5, with a median of $34000.0 recorded in 2022.
- Across the five-year window, Amortization of Deferred Charges tumbled 99.92% in 2023 and surged 3100.0% in 2024, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $34000.0 in 2022, then dropped by 8.82% to $31000.0 in 2023, then soared by 616.13% to $222000.0 in 2024, then surged by 84.23% to $409000.0 in 2025, then soared by 151.34% to $1.0 million in 2026.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $1.0 million, $409000.0, and $222000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.03 Mn |
| Mar 31, 2026 | 1.03 Mn |
| Dec 31, 2025 | 409,000.00 |
| Dec 31, 2025 | 409,000.00 |
| Dec 31, 2024 | 222,000.00 |
| Dec 31, 2024 | 222,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Dec 31, 2022 | 34,000.00 |
| Dec 31, 2022 | 34,000.00 |